Gilead Misses as HIV Sales Founder - Analyst Blog
April 21 2011 - 5:15AM
Zacks
Gilead Sciences Inc. (GILD) reported earnings
per share of 82 cents for the first quarter of 2011, 10 cents below
the Zacks Consensus Estimate of 92 cents and 13 cents below the
year-earlier earnings. The disappointing earnings performance was
due to a weak top-line performance.
First quarter revenues decreased 8% from the prior-year quarter
to $1.93 billion. Total revenues were also much below the Zacks
Consensus Estimate of $2.05 billion. Revenue performance was
disappointing due to a weak performance of the antiviral (HIV)
franchise and lower royalties from Roche (RHHBY)
on Tamiflu sales.
The First Quarter in Detail
Product sales, at $1.86 billion, though up 4% over the prior
year, were down 3% sequentially. The sequential decline in sales
was due to weak performance of antiviral products like Atripla,
Truvada and Viread in US.
Antiviral product sales for the quarter though up 2% year over
year to $1.63 billion were down 4% sequentially. The sequential
drop was due to declines in wholesaler inventories in the US and
purchase cutbacks by certain state funded AIDS Drug Assistance
Program (ADAP) entities in Florida and Texas.
Among the antiviral products, Viread delivered the worst
performance recording sales of $168.4 million, down 7% over the
prior year and 12% on a sequential basis, being affected by
decreased sales volume in Brazil. Atripla sales though up 7% over
the prior year to $744.5 million were down 4% sequentially. Truvada
sales were also down 1.3% sequentially to $673.1 million despite
being up 2% over the prior year.
Other products such as Letairis (for the treatment of pulmonary
arterial hypertension) and Ranexa (for chronic angina) recorded
sales of $62.2 million (up 12% over the prior year) and $68.3
million (up 33%), respectively, thanks to volume growth.
Gilead’s royalty, contract and other revenues plummeted 79% to
$62.5 million based on lower royalties from Roche on Tamiflu sales.
Tamiflu-related royalties during the quarter were $11.1 million as
opposed to $246.3 million in the year-ago period. Demand for
Tamiflu has declined significantly from 2009 levels due to the
waning of the swine flu.
Guidance Reiterated
Despite the first quarter miss, Gilead maintained its previously
provided guidance for 2011. The company expects product revenue in
the range of $7.9 billion to $8.1 billion in 2011, reflecting an
increase of 7% to 10% over 2010 product sales. The Zacks Consensus
sales estimate for 2011 is $8.36 billion. The guidance assumes that
the state ADAP purchasing will resume.
R&D expenses are forecast in a $950 million to $1 billion
band and SG&A expenses are expected in a range of $1 billion to
$1.05 billion. The effective tax rate is expected in the range of
25% - 27%.
Product and Pipeline Update
Gilead has re-filed its new drug application (NDA) to the US
Food and Drug Administration (FDA) for its once daily, single
tablet, fixed dose combination of Truvada and TMC278 (rilpivirine)
as a HIV treatment for adult patients. Earlier, in January this
year, the FDA had issued a refuse-to-file notice for the NDA. The
FDA has assigned a priority review status to the application and
will give its decision on August 10, 2011. We believe the combo
pill is key to long-term growth at Gilead.
In March this year, Gilead announced that its key HIV pipeline
candidate elvitegravir met the primary endpoint in a late-stage
trial. Elvitegravir was shown to be non-inferior to
Merck’s (MRK) Isentress at week 48 in viral load
reduction. Gilead hopes to use the 48-week data from the
elvitegravir study for regulatory filings for both elvitegravir and
the Quad pill. The latter is a fixed dose combination of four
Gilead drugs, elvitegravir, cobicistat, and Truvada (made up of
Emtriva and Viread). The Quad pill is also being studied for the
treatment of HIV.
Data from phase III trials of the Quad pill are expected to be
presented in the third quarter of 2011, which we believe will be
one of the most significant events for the company this year. The
NDA for Quad is expected to be filed in the first quarter of 2012
and that of elvitegravir and cobicistat (being developed as a
booster for protease inhibitors in the treatment of HIV in late
stage trials) are expected during the second quarter of 2012.
Gilead announced that a late stage trial studying Cayston in
cystic fibrosis with Burkholderia cepacia infection failed to show
any benefit in this population. Gilead plans to begin two late
stage studies in patients with bronchiectasis by mid 2011.
In March this year, Gilead announced that the FDA has approved
the removal of potential liver injury warning from the boxed caveat
of the Letairis label. In conjunction with the label change,
patients receiving Letairis will no longer require monthly
monitoring of liver function through blood tests. We believe the
label change would be a definite positive for the uptake of the
drug and lend it a competitive edge over other PAH drugs. In the
same month, Gilead entered into a research collaboration with Yale
School of Medicine for discovery of novel cancer therapies.
The MicroDose Collaboration
In addition to presenting financial results, Gilead announced
that it has entered into a license and collaboration agreement with
MicroDose Therapeutx Inc. for the development and commercialization
of MDT-637, MicroDose's antiviral fusion inhibitor for the
treatment of respiratory syncytial virus (RSV).
Gileadwill support the development of the candidate through
phase IIa, following which it has the option to take on full
clinical development of the product. Gilead will make an
undisclosed upfront payment and provide research funding. MicroDose
is also eligible to receive milestone payments, development fees
and royalties on net sales, if the drug is marketed. An
Investigational New Drug (IND) for the candidate will be filed by
MicroDose soon with an aim to begin phase I trials this year.
Our Recommendation
Currently, we have a Neutral recommendation on Gilead, which is
supported by a Zacks #3 Rank (short term hold). Despite the
disappointing performance this quarter, we remain optimistic on the
growth potential of Gilead’s HIV franchise drugs, Truvada and
Atripla. The fundamentals of the HIV franchise are strong as
demonstrated by patient demand and prescription growth in the first
quarter despite the declines. The ADAP fluctuation seems temporary.
We are also encouraged by Gilead’s strong HIV pipeline. However,
the company’s HIV drugs are facing patent challenges from generic
companies. Gilead’s revenues also continue to be unfavorably
impacted by pricing pressures in Europe and currency
fluctuation.
GILEAD SCIENCES (GILD): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
Zacks Investment Research
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024